IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Summit Trail Advisors LLC

Summit Trail Advisors LLC lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 501 shares of the company’s stock after selling 61 shares during the quarter. Summit Trail Advisors LLC’s holdings in IDEXX Laboratories were worth $278,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of IDXX. Gotham Asset Management LLC boosted its holdings in IDEXX Laboratories by 79.9% during the third quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock worth $7,620,000 after buying an additional 7,741 shares in the last quarter. NewEdge Wealth LLC increased its stake in shares of IDEXX Laboratories by 30.4% in the 3rd quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock valued at $279,000 after purchasing an additional 149 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in IDEXX Laboratories by 25.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock worth $24,196,000 after purchasing an additional 8,831 shares during the period. Carderock Capital Management Inc. boosted its position in IDEXX Laboratories by 35.7% during the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock worth $9,112,000 after purchasing an additional 4,315 shares in the last quarter. Finally, Mitchell Capital Management Co. boosted its position in IDEXX Laboratories by 1.3% during the third quarter. Mitchell Capital Management Co. now owns 6,372 shares of the company’s stock worth $2,786,000 after purchasing an additional 79 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.7 %

NASDAQ IDXX opened at $487.07 on Thursday. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The firm has a market cap of $40.23 billion, a PE ratio of 47.15, a P/E/G ratio of 3.78 and a beta of 1.27. The business’s fifty day simple moving average is $519.60 and its 200-day simple moving average is $514.34. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The business had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. During the same quarter in the prior year, the company posted $2.05 EPS. The company’s quarterly revenue was up 8.8% on a year-over-year basis. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.05 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on IDXX. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, May 2nd. JPMorgan Chase & Co. raised their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. The Goldman Sachs Group boosted their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Finally, Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price on the stock. in a research report on Tuesday, January 30th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $580.88.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.